AIDS CLINICAL ROUNDS
The UC San Diego AntiViral Research Center sponsors weekly
presentations by infectious disease clinic...
AN AIDS-DEFINING ILLNESS PRESENTING
DURING ACUTE RETROVIRAL SYNDROME:
A CASE DISCUSSION AND REVIEW OF THE
LITERATURE

FEBR...
Disclosures




I have no relevant financial relationships with any
commercial supporters.
Unlabeled/Investigational pro...
Question


Of the following, what is the most frequently
described opportunistic infection in adult patients
with acute r...
Answer-B


Pneumocystis pneumonia
 Along

with oral and esophageal candidiasis, the most
commonly described OI in ARS
 ...
Case




CC: New diagnosis of HIV
HPI: 21 y/o MSM college student diagnosed with
acute retroviral syndrome 2 months prio...
Pertinent History






Presented with gastrointestinal symptoms, associated
lethargy, and decreased appetite in early ...
Physical Exam


Initial Presentation: 8 Oct 2013
 Afebrile;

HR 62bpm; BP (111/68); RR 16/min; O2

96% RA
 Only diffuse...
Labs
WBC

Neut

Bands

Lymph

CBC 10/8/2013

3.8

48%

NA

40%

CBC 11/1/2013

20.0

24%

37%

13%

Tbili

AST

ALT

Alk P...
Labs
Viral hepatitis panel

Negative

C-diff PCR

Negative

Stool Culture

Negative

Fecal leukocytes

Negative

Stool Cry...
HIV Labs
1 Nov 2013

8 Jan 2014

CD4 count

524/6%

605/15%

390/13%

CD8

8054/0.07

2823/0.21

2214/0.18

VL



3 Dec 2...
CT Image 8 Oct 2013
CT Image 1 Nov 2013
Hospital Course


Upper and lower endoscopy


Upper
Stomach- moderate gastropathy, mild patchy antral gastropathy
 Smal...
Endoscopy Images
Endoscopy Images
Endoscopy Images
Pathology




Duodenal mucosa with mild intraepithelial
lymphocytosis and focal villous blunting
Small and large bowel w...
Pathology- H&E
Pathology- Immunohistochemical
Discharged






Diagnosed with CMV colitis/enteritis and HIV
infection
Started on IV ganciclovir, transitioned to oral...
Clinical Questions






How often is acute seroconversion marked by an
opportunistic infection, namely CMV colitis?
Wh...
Acute Retroviral Syndrome & OIs




Acute Retroviral Syndrome syndrome occurs in 1090% of acute HIV infections (Sterling...
Other OIs in Acute Retroviral Syndrome


Remainder of literature is description of case
reports
 M.

Kansasii
 Cytomega...
CMV in HIV








Historically a disease of chronic infection with
progression to Acquired Immunodeficiency Syndrome
...
CMV Disease in ARS




2-3 published case reports of CMV gastrointestinal
disease during ARS (none with indeterminate WB...
Evaluation for CMV in ARS


CMV testing
 Documentation

of IgG and IgM serology status

 CMV

DNA PCR
 Tissue specific...
Evaluation for CMV in ARS


Early reports in pre ART era
 Few

documented CMV complications with acute HIV
infection
 S...
CD4 Response in ARS with CMV
Publication

Diagnosis

CD4 (Acute)

CD4 (Conv.)

VL (copies/ml)

Bonetti (1989)

ARS (p)

14...
Summary of Cases




Data across cases changes with era of AIDS epidemic
CD4 count role not completely documented or
exp...
Question


What constellation of symptoms would represent the
highest pretest probability for primary HIV infection?
A) 1...
Answer-C




Prospective cohort from UCSF explored systemic
complaints in patients being tested for HIV with risk
factor...
Recognition of Seroconversion


Early identification
 Allows

for appropriate screening
 Interventions during highly tr...
Prospective Cohort- ARS Symptoms

Hecht 2002 (UCSF)
Prospective Cohort- ARS Symptoms

Hecht 2002
Prospective Cohort- Viral Load and
Symptoms

Kelley 2007
Question


According to recent CDC assessments, the estimated
rate of primary drug resistance in treatment-naïve
patients...
Answer- A


A-14.6%: CDC data from 2006 from 10 states
and 1 public health department published in 2010
(Wheeler, et al. ...
Transmitted Resistance- Testing


Primary resistance in U.S. estimated at 8.3% (2004)

Sax 2004
Sax, 2004
Resistance Testing In Unknown Duration
of Infection

Smith, 2007
Transmitted Resistance- Recent
Estimates

Huang, 2007
Transmitted Resistance- Recent
Estimates


ARV resistance- 12.1%
 NNRTI-

9.8%
 NRTI- 4.5%
 PI- 1.8%


Predictors
 M...
Specific NNRTI Mutation Prevalence

Wheeler 2006
A Regimen for Our Patient
1 Nov 2013

8 Jan 2014

CD4 count

524/6%

605/15%

390/13%

CD8

8054/0.07

2823/0.21

2214/0.1...
Question


True or false:
Elvitegravir/cobicistat/tenofovir/emtricitabine
(“Quad pill”) has been FDA approved for use in
...
Answer- False




Original trials excluded patients with NRTI or NNRTI
or PI mutations
Source- http://clinicaltrials.gov...
Unpublished Data

K White*, et al. Emergent Drug Resistance from the HIV-1 Phase 3 Elvitegravir/Cobicistat/Emtricitabine/T...
K White*, et al. Emergent Drug Resistance from the HIV-1 Phase 3 Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxi...
Our Patient


Experienced an AIDS-defining illness at diagnosis
 Exceedingly

rare event with unknown implications on
pr...
Clinical Plan




Patient has exhibited insight into complexities of his
diagnosis
Discuss with patient protease inhibit...
Works Consulted






































1. Sterling T., Haisson R. General clinical ma...
Thank You





Dr. Blanchard, MD
UCSD Pathology department
UCSD GI Department
Dr Bendin, MD, UCSD Med/Peds Resident
Upcoming SlideShare
Loading in …5
×

An AIDS-Defining Illness Presenting during Acute Retroviral Syndrome: A Case Discussion and Review of the Literature

1,285 views

Published on

Wesley Campbell, MD, of U.S. Navy Medicine, presents "An AIDS-Defining Illness Presenting during Acute Retroviral Syndrome: A Case Discussion and Review of the Literature" for AIDS Clinical Rounds at UC San Diego

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,285
On SlideShare
0
From Embeds
0
Number of Embeds
8
Actions
Shares
0
Downloads
16
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

An AIDS-Defining Illness Presenting during Acute Retroviral Syndrome: A Case Discussion and Review of the Literature

  1. 1. AIDS CLINICAL ROUNDS The UC San Diego AntiViral Research Center sponsors weekly presentations by infectious disease clinicians, physicians and researchers. The goal of these presentations is to provide the most current research, clinical practices and trends in HIV, HBV, HCV, TB and other infectious diseases of global significance. The slides from the AIDS Clinical Rounds presentation that you are about to view are intended for the educational purposes of our audience. They may not be used for other purposes without the presenter’s express permission.
  2. 2. AN AIDS-DEFINING ILLNESS PRESENTING DURING ACUTE RETROVIRAL SYNDROME: A CASE DISCUSSION AND REVIEW OF THE LITERATURE FEBRUARY 21, 2014 LCDR Wesley Campbell, MC, USN, PGY-4
  3. 3. Disclosures   I have no relevant financial relationships with any commercial supporters. Unlabeled/Investigational products and/or services will be mentioned in this CME offering.
  4. 4. Question  Of the following, what is the most frequently described opportunistic infection in adult patients with acute retroviral syndrome?  A) Herpes zoster  B) Pneumocystis pneumonia  C) CMV colitis  D) CMV pneumonitis  E) Cryptococcal meningitis
  5. 5. Answer-B  Pneumocystis pneumonia  Along with oral and esophageal candidiasis, the most commonly described OI in ARS  OIs are rare in ARS and felt to be a consequence of transient CD4 T-cell depletion; nadir typically occurs 36 weeks post infection
  6. 6. Case   CC: New diagnosis of HIV HPI: 21 y/o MSM college student diagnosed with acute retroviral syndrome 2 months prior in setting of prolonged gastrointestinal complaints
  7. 7. Pertinent History    Presented with gastrointestinal symptoms, associated lethargy, and decreased appetite in early October with brief observation on general surgery to rule out appendicitis. Diagnosed with viral enteritis. After discharge from surgery service, spent time in Mexico with hospital admission there for ongoing symptoms. Received IV fluids, antibiotics and evaluation for hepatitis. Evaluated on 1 November in ED due to 2 days of worsening GI symptoms. Initiated on ciprofloxacin/metronidazole for colitis.
  8. 8. Physical Exam  Initial Presentation: 8 Oct 2013  Afebrile; HR 62bpm; BP (111/68); RR 16/min; O2 96% RA  Only diffuse abdominal discomfort on exam  Re-presentation: 1 Nov 2013  Afebrile; HR 104bpm; BP (106/65); RR 16/min; O2 97% RA  Only diffuse tenderness documented
  9. 9. Labs WBC Neut Bands Lymph CBC 10/8/2013 3.8 48% NA 40% CBC 11/1/2013 20.0 24% 37% 13% Tbili AST ALT Alk Phos LFTs 10/8/2013 0.6 52 59 67 LFTs 11/1/2013 1.1 93 85 85
  10. 10. Labs Viral hepatitis panel Negative C-diff PCR Negative Stool Culture Negative Fecal leukocytes Negative Stool Crypto Ag Negative Stool O&P Negative HIV rapid Positive Giardia Ag Negative RPR Negative Quantiferon Negative Toxoplasmosis serology Negative EBV serologies Negative CMV PCR 16,169 copies CMV titers Ig ordered, not collected
  11. 11. HIV Labs 1 Nov 2013 8 Jan 2014 CD4 count 524/6% 605/15% 390/13% CD8 8054/0.07 2823/0.21 2214/0.18 VL  3 Dec 2013 1,096,247 4,010,146 532,574 Genotype B  K103S mutation  HIV ELISA pos; Indeterminate western blot (1Nov)
  12. 12. CT Image 8 Oct 2013
  13. 13. CT Image 1 Nov 2013
  14. 14. Hospital Course  Upper and lower endoscopy  Upper Stomach- moderate gastropathy, mild patchy antral gastropathy  Small hiatal hernia  Mild duodenitis  Normal esophagus   Lower Patchy colitis throughout colon with ulcer on ileocecal valve  Patchy ileitis  Rectal inflammation  Small internal hemorrhoids 
  15. 15. Endoscopy Images
  16. 16. Endoscopy Images
  17. 17. Endoscopy Images
  18. 18. Pathology   Duodenal mucosa with mild intraepithelial lymphocytosis and focal villous blunting Small and large bowel with scattered Cytomegalovirus (CMV) inclusions
  19. 19. Pathology- H&E
  20. 20. Pathology- Immunohistochemical
  21. 21. Discharged    Diagnosed with CMV colitis/enteritis and HIV infection Started on IV ganciclovir, transitioned to oral, diarrhea resolved 3weeks thereafter Enrolled in AVRC Acute HIV study
  22. 22. Clinical Questions    How often is acute seroconversion marked by an opportunistic infection, namely CMV colitis? What symptoms predominate in ARS that would have lead to earlier testing? What options are there for first-line therapy in setting of baseline resistance mutation and high viral load?
  23. 23. Acute Retroviral Syndrome & OIs   Acute Retroviral Syndrome syndrome occurs in 1090% of acute HIV infections (Sterling, PPID) Opportunistic Infections in acute retroviral syndrome (ARS) are even more rare  Oral/esophageal candidiasis  Pneumocystis pneumonia  Cryptococcal meningitis
  24. 24. Other OIs in Acute Retroviral Syndrome  Remainder of literature is description of case reports  M. Kansasii  Cytomegalovirus pneumonia and hepatitis  Cytomegalovirus colitis  Cytomegalovirus encephalitis  Focal segmental glomerulosclerosis- HIV nephropathy
  25. 25. CMV in HIV     Historically a disease of chronic infection with progression to Acquired Immunodeficiency Syndrome (AIDS) Pre-ART: Occurred in 21-44% of patients with spectrum of targeted organ to disseminated disease (Masur 1996) Today: Estimated at 0.75-3.2 cases per 100 personyears (Salzberger 2005) Detected in up to 30% of HIV patients with CD4<100
  26. 26. CMV Disease in ARS   2-3 published case reports of CMV gastrointestinal disease during ARS (none with indeterminate WB) Typical mononucleosis syndrome plus: +/-Oral lesions  Nausea/vomiting  Moderate transaminitis   Discussion of primary infection vs. reactivation of CMV
  27. 27. Evaluation for CMV in ARS  CMV testing  Documentation of IgG and IgM serology status  CMV DNA PCR  Tissue specific immunohistochemical staining  Hepatic  Pulmonary  Colonic biopsy
  28. 28. Evaluation for CMV in ARS  Early reports in pre ART era  Few documented CMV complications with acute HIV infection  Serologies used to discuss acute co-infection  Post ART  More routine use of advanced testing at diagnosis
  29. 29. CD4 Response in ARS with CMV Publication Diagnosis CD4 (Acute) CD4 (Conv.) VL (copies/ml) Bonetti (1989) ARS (p) 1410 30 NT Bonetti (1989) ARS (p) NT 530 NT Raffi (1990) ARS (p) NT NT NT Schindler (1990) ARS (p) NT NT NT Nguyen (1991) ARS (p) NT NT NT Gupta (1993) Colitis (p) 255 1098 Qualitative Berger (1996) Encephalitis (p) 458 (19%) 1,270 (37.1%) 121,150 Jouveshomme (1997) Alveolitis (p) 1020 999 NT Smith (2000) Colitis (r) NT 800 NT Vietri (2002) Esophagitis (?) 452 643 160,000 Capetti (2006) Colitis (?) (WB positive at diagnosis) 1305 NT 750,000 Von Both (2008) Pancolitis (r) (WB positive) 164 932 (2yrs) 3,080,000 Hong (2011) Pneumonia/hepatitis (P) 242 460 6.7log ARS- Acute Retroviral Syndrome; (p)-primary CMV; (r)- reactivation CMV; (?) unknown CMV status
  30. 30. Summary of Cases   Data across cases changes with era of AIDS epidemic CD4 count role not completely documented or explained in ARS, but likely represents decreased functional count   Our patient had a CD4 count of 6% total lymphocyte count HIV viral load over 100,000 copies may have some correlation to CMV infection  Our patient had over 1 million copies
  31. 31. Question  What constellation of symptoms would represent the highest pretest probability for primary HIV infection? A) 19 y/o MSM who is in a monogamous relationship with an HIV (+) partner with 5 days of headache, subjective fever, night sweats  B) 22 y/o heterosexual male with 1 week of malaise, subjective fevers and vomiting who had an unprotected sexual encounter 2 weeks prior  C) 20 y/o heterosexual male with multiple unprotected sexual encounters 2 months prior, with intermittent fever, rash, loss of appetite, myalgias, and loss of energy  *based on 2002 prospective cohort at UCSF
  32. 32. Answer-C   Prospective cohort from UCSF explored systemic complaints in patients being tested for HIV with risk factors for HIV exposure in preceding 3 months Fever was only symptom highly sensitive for HIV infection, while combinations of symptoms increased specificity and likelihood ratio for primary infection  Fever with rash 91% specific in adult patients  Diarrhea was of low sensitivity 46%
  33. 33. Recognition of Seroconversion  Early identification  Allows for appropriate screening  Interventions during highly transmissible period  “Mononucleosis-Like” syndrome  Nonspecific complaints often overlooked  Requires exploration of possible risk factors  What constellation of symptoms would trigger evaluation?
  34. 34. Prospective Cohort- ARS Symptoms Hecht 2002 (UCSF)
  35. 35. Prospective Cohort- ARS Symptoms Hecht 2002
  36. 36. Prospective Cohort- Viral Load and Symptoms Kelley 2007
  37. 37. Question  According to recent CDC assessments, the estimated rate of primary drug resistance in treatment-naïve patients is:  A) 14.6%  B) 25%  C) 8.3%  D) 12.1%
  38. 38. Answer- A  A-14.6%: CDC data from 2006 from 10 states and 1 public health department published in 2010 (Wheeler, et al. 2010)    B- 25%: Estimates for San Diego County with small cohort (Smith, et al. 2007) C- 8.3%: 2004 estimates (Weinstock, et al. 2004) D- 12.1%: East Coast cohort, industry sponsored through Merk (Huang, et al. 2008)
  39. 39. Transmitted Resistance- Testing  Primary resistance in U.S. estimated at 8.3% (2004) Sax 2004
  40. 40. Sax, 2004
  41. 41. Resistance Testing In Unknown Duration of Infection Smith, 2007
  42. 42. Transmitted Resistance- Recent Estimates Huang, 2007
  43. 43. Transmitted Resistance- Recent Estimates  ARV resistance- 12.1%  NNRTI- 9.8%  NRTI- 4.5%  PI- 1.8%  Predictors  MSM  CD<500 Huang, 2007
  44. 44. Specific NNRTI Mutation Prevalence Wheeler 2006
  45. 45. A Regimen for Our Patient 1 Nov 2013 8 Jan 2014 CD4 count 524/6% 605/15% 390/13% CD8 8054/0.07 2823/0.21 2214/0.18 VL  3 Dec 2013 1,096,247 4,010,146 532,574 Expressed interest in a single-pill regimen or oncedaily regimen  Ease of attending classes  Social constraints
  46. 46. Question  True or false: Elvitegravir/cobicistat/tenofovir/emtricitabine (“Quad pill”) has been FDA approved for use in treatment-naïve patients with primary resistance to NRTIs and NNRTIs.  A) True  B) False
  47. 47. Answer- False   Original trials excluded patients with NRTI or NNRTI or PI mutations Source- http://clinicaltrials.gov/show/NCT00869557
  48. 48. Unpublished Data K White*, et al. Emergent Drug Resistance from the HIV-1 Phase 3 Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Studies through Week 96 Presented at CROI 2013
  49. 49. K White*, et al. Emergent Drug Resistance from the HIV-1 Phase 3 Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Studies through Week 96 Presented at CROI 2013
  50. 50. Our Patient  Experienced an AIDS-defining illness at diagnosis  Exceedingly rare event with unknown implications on progression of disease or response to therapy  CMV enteritis resolution after short course of valganciclovir and rebound of his CD4 count implies limited disease
  51. 51. Clinical Plan   Patient has exhibited insight into complexities of his diagnosis Discuss with patient protease inhibitor vs. integrase inhibitor-based regimen given available data Choices of ART influenced by early genotype testing and viral load  If placed on the “Quad pill” most likely resistance mutation to emerge is M184V and becomes apparent by approximately12 weeks*  At last visit, treatment regimen was yet to be determined  *K White*, et al. Emergent Drug Resistance from the HIV-1 Phase 3 Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Studies through Week 96 Presented at CROI 2013
  52. 52. Works Consulted                       1. Sterling T., Haisson R. General clinical manifestations of Human Immunodeficiency Virus infection (Including the acute retroviral syndrome and oral, cutaneous, renal, ocular, metabolic, and cardiac diseases). In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 7th ed. Philadelphia: Churchill Livingstone; 2009. p. 1711-13. 2. Masur H, Whitcup SM, Cartwright C, Polis M, Nussenblatt R. Advances in the management of AIDS-related cytomegalovirus retinitis. Ann Intern Med. 1996;125(2):126–36. 3. Salzberger B, Hartmann P, Hanses F, Uyanik B, Cornely OA, Wöhrmann A, et al. Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy. Infection. 2005 Oct;33(5-6):345–9. 4. Bonetti A, Weber R, Vogt MW, Wunderli W, Siegenthaler W, Lüthy R. Co-infection with human immunodeficiency virus-type 1 (HIV-1) and cytomegalovirus in two intravenous drug users. Ann Intern Med. 1989;111(4):293–6. 5. Raffi F, Boudart D, Billaudel S. Acute co-infection with human immunodeficiency virus (HIV) and cytomegalovirus. Ann Intern Med. 1990 Feb 1;112(3):234–5. 6. Schindler JM, Neftel KA. Simultaneous primary infection with HIV and CMV leading to severe pancytopenia, hepatitis, nephritis, perimyocarditis, myositis, and alopecia totalis. Klin Wochenschr. 1990;68(4):237–40. 7. Nguyen C, Lebel F. Acute retroviral syndrome complicated by cytomegalovirus and hepatitis A coinfection. J Infect Dis. 1991 Jul;164(1):219–20. 8. Gupta KK. Acute immunosuppression with HIV seroconversion. N Engl J Med. 1993 Jan 28;328(4):288–9. 9. Berger DS, Bucher G, Nowak JA, Gomatos PJ. Acute primary human immunodeficiency virus type 1 infection in a patient with concomitant cytomegalovirus encephalitis. Clin Infect Dis. 1996;23(1):66–70. 10. Jouveshomme S, Couderc LJ, Ferchal F, Vignon D, Autran B, Balloul E, et al. Lymphocytic alveolitis after primary HIV infection with CMV coinfection. Chest. 1997 Oct;112(4):1127–8. 11. Smith PR, Glynn M, Sheaff M, Aitken C. CMV colitis in early HIV infection. Int J STD AIDS. 2000 Nov 1;11(11):748–50. 12. Vietri NJ, Skidmore PJ, Dooley DP. Esophageal ulceration due to cytomegalovirus infection in a patient with acute retroviral syndrome. Clin Infect Dis Off Publ Infect Dis Soc Am. 2002 Jan 1;34(1):E14–15. 13. Hong K-W, Kim SI, Kim YJ, Wie SH, Kim YR, Yoo J-H, et al. Acute cytomegalovirus pneumonia and hepatitis presenting during acute HIV retroviral syndrome. Infection. 2011 Jan 19;39(2):155–9. 14. Capetti A, Piconi S, Magni C, Quirino T, Trabattoni D, Clerici M. Unusual presentation of acute cytomegalovirus disease during primary HIV-1 infection: antigen-specific T-cell response analyses and clinical outcome. AIDS Lond Engl. 2006 Jul 13;20(11):1566–7. 15. Von Both U, Laffer R, Grube C, Bossart W, Gaspert A, Gu nthard HF. Acute Cytomegalovirus Colitis Presenting during Primary HIV Infection: an Unusual Case of an Immune Reconstitution Inflammatory Syndrom. Clin Infect Dis. 2008 Feb 15;46(4):e38–e40. 16. Hecht FM, Busch MP, Rawal B, Webb M, Rosenberg E, Swanson M, et al. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. Aids. 2002;16(8):1119–29. 17. Kelley CF, Barbour JD, Hecht FM. The relation between symptoms, viral load, and viral load set point in primary HIV infection. J Acquir Immune Defic Syndr 1999. 2007 Aug 1;45(4):445–8. 18. Hakre S, Brett-Major DM, Singer DE, O’Connell RJ, Sateren WB, Sanchez JL, et al. Medical encounter characteristics of HIV seroconverters in the US Army and Air Force, 2000–2004. JAIDS J Acquir Immune Defic Syndr. 2011;56(4):372–80. 19. Sax PE, Islam R, Walensky RP, Losina E, Weinstein MC, Goldie SJ, et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis. 2005;41(9):1316–23. 20. Smith D, Moini N, Pesano R, Cachay E, Aiem H, Lie Y, et al. Clinical utility of HIV standard genotyping among antiretroviral-naive individuals with unknown duration of infection. Clin Infect Dis. 2007;44(3):456–8. 21. Huang H-Y, Daar E, Sax P, Young B, Cook P, Benson P, et al. The prevalence of transmitted antiretroviral drug resistance in treatment-naïve patients and factors influencing first-line treatment regimen selection. HIV Med. 2008 May;9(5):285–93. 22. Wheeler WH, Ziebell RA, Zabina H, Pieniazek D, Prejean J, Bodnar UR, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.–2006: AIDS. 2010 May;24(8):1203–12.
  53. 53. Thank You     Dr. Blanchard, MD UCSD Pathology department UCSD GI Department Dr Bendin, MD, UCSD Med/Peds Resident

×